PharmEasy Exploring a Merger With Thyrocare: What It Could Mean for Unlisted Shareholders

PharmEasy's parent, API Holdings, is exploring a merger with Thyrocare, the listed diagnostics chain it controls, ET Now reported on October 27, 2026. If it happens, it would be the long-discussed "reverse merger" that gives PharmEasy a stock-market listing without a traditional IPO. Here is what is known, what is not, and what it could mean if you hold or are thinking of buying PharmEasy unlisted shares.

What was reported, and what wasn't

• The report: ET Now said on October 27 that PharmEasy is exploring a merger with Thyrocare.
• No confirmation yet: as of the evening of October 27, neither API Holdings nor Thyrocare had confirmed talks in an exchange filing. Thyrocare's latest filings were about its board meeting on October 29 to approve September-quarter results.
• No terms: no structure, swap ratio, valuation or timeline has been made public.
• Market reaction: Thyrocare closed at ₹493 on NSE on October 27, up 4.8% on the day. Its 52-week range is ₹343 to ₹662.

"Exploring" is a long way from "agreed". Treat this as an early signal, not a deal.

Why it is back on the table now

Merger talk has followed PharmEasy for years. What has changed in 2026 is that management has been clearing the obstacles it set for itself:

1. Debt is gone. On August 14, 2026, API Holdings repaid its remaining ₹1,050 crore of term debt, funded mainly by selling Thyrocare shares. The pledge on its Thyrocare stake was released.
2. The holding structure is simpler. Thyrocare used to be held through a subsidiary, Docon Technologies. Docon was merged into API Holdings with effect from September 3, 2026, so API now owns its 51.02% of Thyrocare directly.
3. Subsidiaries are being tidied up. API is asking its shareholders, through a postal ballot that closes on November 15, to approve buying out Lightrock's 31.33% of its hospital-supply arm Aknamed. It would pay with about 53.4 crore new API shares at ₹6.51 each (about ₹347.5 crore), making Aknamed wholly owned.
4. Losses are shrinking. Group revenue was ₹6,618.5 crore in FY2026 and EBITDA turned positive for the first time at ₹38 crore, though the net loss was still ₹520 crore. Excluding Thyrocare, the EBITDA loss narrowed from ₹637 crore in FY2024 to ₹396 crore in FY2025 and ₹168 crore in FY2026.

In August, Rahul Guha, who is CEO of both API Holdings and Thyrocare, ruled out an immediate reverse merger. He set two conditions: the group had to be debt-free (now done) and profitable before tax excluding Thyrocare, which he expected by the end of FY2027. In October he said all options, a Thyrocare merger or a separate IPO, remained open. Exploring a merger now fits that path; it does not mean the second condition has been met.

How a reverse merger would work

In the structure most often discussed, the unlisted parent merges into its listed subsidiary:

1. API Holdings merges into Thyrocare. Thyrocare, already listed on NSE and BSE, is the surviving company. It would end up owning PharmEasy, the Retailio/Ascent chemist-supply business, Aknamed and its own diagnostics labs.
2. API shareholders get Thyrocare shares. Every API Holdings share would be swapped for a fixed number of new Thyrocare shares, set by a swap ratio.
3. API's existing Thyrocare stake is cancelled. The 8.12 crore Thyrocare shares API owns today would not survive the merger; API's shareholders would hold Thyrocare directly instead.
4. Approvals take time. A scheme like this needs a registered valuer's report and a fairness opinion, no-objection letters from the stock exchanges and SEBI, approval from Thyrocare's shareholders (typically including a majority of its public shareholders, because API is the promoter), and finally the NCLT. These schemes usually take a year or more from board approval.

The swap-ratio maths

The swap ratio is everything for an unlisted holder, and it will be set by valuers, not by today's unlisted quote. Here is how it would look at Thyrocare's October 27 price of ₹493, for different values the deal could put on one API Holdings share:

Illustration only, at Thyrocare's October 27 close. Real ratios are set by registered valuers when a scheme is announced.

Two things follow:

• If the deal values API below today's unlisted price, the unlisted price would likely fall to match it. The ₹6.51 price API itself is using in the Aknamed swap is a useful marker: it is about 6% below today's ₹6.95 ask.
• After the swap, your value moves with Thyrocare's share price. A 20% fall in Thyrocare between the announcement and allotment would cut what you receive by 20%.

A sum-of-the-parts check

API's 8.12 crore Thyrocare shares were worth about ₹4,000 crore at ₹493. On roughly 1,804 crore API shares on a fully diluted basis (the count in the Aknamed ballot notice), that is about ₹2.20 of every API share.

So at a ₹6.95 ask, the market is paying about ₹4.75 a share, or around ₹8,500 crore, for everything else: the PharmEasy app, the Retailio/Ascent distribution business and Aknamed. Those businesses brought in roughly ₹5,800 crore of FY2026 revenue (group revenue minus Thyrocare's ₹829 crore) and were still loss-making at the EBITDA level. In the Aknamed deal, API valued Aknamed alone at about ₹1,100 crore.

That gap is what a merger would test. Thyrocare's own shareholders, who own a profitable lab chain (FY2026 net profit ₹163 crore), will have to agree that the rest of the group is worth what the swap ratio implies.

What it could mean for you

If you hold PharmEasy unlisted shares:

• The upside is a route to a listing. A merger would turn illiquid unlisted paper into shares you can sell on NSE and BSE, without waiting for a separate IPO.
• The ratio could disappoint. Thyrocare's minority shareholders and SEBI will push for a ratio that protects them, and that may value API below the unlisted quote.
• It is slow. Even a quick scheme takes a year or more, and new shares may carry a lock-in. Our guide to lock-in rules for pre-IPO buyers explains how they usually work.

If you are thinking of buying now:

• The PharmEasy unlisted price jumped from ₹6.25 to ₹9.95 in a few days in mid-September, then slipped back to around ₹7. Merger headlines can cause similar spikes. Buy on the business and a realistic swap value, not the headline.
• One lot is 5,000 shares, about ₹34,750 at ₹6.95. Settlement is an off-market transfer of API Holdings equity, ISIN INE0DJ201029.

What to watch next

1. Thyrocare's results on October 29. The board meets to approve September-quarter numbers, followed by an earnings call at 6 pm. Expect analysts to ask about the merger.
2. An exchange clarification. When a listed company is named in a merger report, the exchanges often ask it to confirm or deny. Thyrocare's reply will tell us how real the talks are.
3. The Aknamed vote. The postal ballot closes on November 15 and results are due by November 22.
4. Profitability excluding Thyrocare. This was management's own pre-condition. Watch API's half-year numbers.

The bottom line

The report fits a clear pattern: PharmEasy has repaid its debt, simplified how it holds Thyrocare and is buying out minority stakes in its subsidiaries. A merger into Thyrocare is the obvious next step towards a listing. But nothing is filed, management's own profitability test has not been passed yet, and the swap ratio could value PharmEasy below today's unlisted price. If you own it, this is good news for your exit route, not a guarantee of a better price. If you are buying, price in the swap risk and the time it will take.

Live price, lot size and full financials are on the PharmEasy (API Holdings) share page. For background, read our earlier posts on the Thyrocare reverse-merger route and API Holdings' debt reduction.

Disclaimer: This article is for information and education only and is not investment advice. The merger report is from ET Now (October 27, 2026) and had not been confirmed by either company at the time of writing. Thyrocare price data is from NSE via Screener (October 27 close). Management comments are from Medical Buyer/CNBC-TV18 (August 17, 2026) and Moneycontrol (October 5, 2026). Aknamed swap terms are from API Holdings' postal-ballot notice as summarised by UnlistedZone (October 23, 2026). Swap ratios and sum-of-the-parts figures are ShareSaathi's own illustrations. Unlisted shares are illiquid, prices are indicative dealer quotes, and a listing is never guaranteed. Please consult a SEBI-registered investment adviser before investing.